Abichabki, Nathália
Zacharias, Luísa V.
Moreira, Natália C.
Bellissimo-Rodrigues, Fernando
Moreira, Fernanda L.
Benzi, Jhohann R. L.
Ogasawara, Tânia M. C.
Ferreira, Joseane C.
Ribeiro, Camila M.
Pavan, Fernando R.
Pereira, Leonardo R. L.
Brancini, Guilherme T. P.
Braga, Gilberto Ú. L.
Zuardi, Antonio W.
Hallak, Jaime E. C.
Crippa, José A. S.
Lanchote, Vera L.
Cantón, Rafael
Darini, Ana Lúcia C.
Andrade, Leonardo N.
Funding for this research was provided by:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (8887.369851/2019-00)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (130766/2021-6)
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, São Paulo State, Brazil), and Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (CNPq/FAPESP 14/50891-1)
University Global Partnership Network (Global Priorities in Cannabinoid Research Excellence Program)
Pró-Reitoria de Pesquisa da USP (18.1.796.60.2 grupo 057)
Article History
Received: 27 October 2021
Accepted: 4 March 2022
First Online: 19 April 2022
Competing interests
: JASC is a member of the International Advisory Board of the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE)—National Health and Medical Research Council (NHMRC). JASC and JECH have received travel support to attend scientific meetings and personal consultation fees from BSPG-Pharm. JASC, JECH, and AWZ are coinventors of the patent “Fluorinated CBD compounds, compositions and uses thereof. Pub. No.: WO/2014/108899. International Application No.: PCT/IL2014/050023,” Def. US number Reg. 62193296; July 29, 2015; INPI on August 19, 2015 (BR1120150164927; Mechoulam R, Zuardi AW, Kapczinski F, Hallak JEC, Guimarães FS, Crippa JAS, Breuer A). Universidade de São Paulo (USP) has licensed this patent to Phytecs Pharm (USP Resolution No. 15.1.130002.1.1) and has an agreement with Prati-Donaduzzi to “develop a pharmaceutical product containing synthetic CBD and prove its safety and therapeutic efficacy in the treatment of epilepsy, schizophrenia, Parkinson’s disease, and anxiety disorders.” JASC, JECH, and AWZ are coinventors of the patent “Cannabinoid-containing oral pharmaceutical composition, method for preparing and using same,” INPI on September 16, 2016 (BR 112018005423-2). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The other authors declare that they have no conflicts of interest.